Maternal Serum Stathmin-1 Levels in Preeclampsia

Completed

• Conditions: Pre-Eclampsia

• Registration Number: NCT06623955
• Lead Sponsor: Başakşehir Çam & Sakura City Hospital

Brief Summary

This study investigates maternal serum Stathmin-1 (STMN-1) levels in pregnancies complicated by preeclampsia and severe preeclampsia, compared to healthy pregnancies. The aim is to explore potential differences in STMN-1 levels among these groups to better understand its role in preeclampsia pathophysiology. Maternal serum STMN-1 levels will be measured between 32-34 weeks of gestation, and patients will be monitored until delivery to assess whether they develop preeclampsia or severe preeclampsia.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-01-01
• Primary Completion: 2024-01-01
• Study Completion: 2024-03-01
• Status Verified: 2024-09
• Study First Submitted: 2024-09-24
• Study First Submitted QC: 2024-09-30
• Last Update Submitted: 2024-09-30
• Study First Posted: 2024-10-02
• Last Update Posted: 2024-10-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 84

Inclusion Criteria

• Clinical diagnosis of Preeclampsia: Defined by New-onset hypertension (Systolic Blood Pressure ≥140 mmHg and/or Diastolic Blood Pressure ≥90 mmHg) after 20 weeks of gestation, with or without proteinuria.
• Clinical diagnosis of Severe Preeclampsia: Defined by criteria such as severe hypertension (systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg), organ dysfunction (renal insufficiency, liver involvement, neurological complications), thrombocytopenia, pulmonary edema, or fetal growth restriction.
• Control Group: Healthy pregnancies without preeclampsia

Exclusion Criteria

• Multiple Pregnancies
• Pregestational Diabetes
• Chronic Hypertension
• Systemic Diseases (Chronic kidney disease, autoimmune diseases)
• Fetal Anomalies
• Premature Rupture of Membranes

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Maternal Serum Stathmin-1	Up to 8 weeks (Patients will be followed from inclusion in the study until the end of their pregnancy.)	To compare Stathmin-1 Levels between the pre-eclampsia and the control group.

Trial Locations

Locations (1)

Cam and Sakura City Hospital; 🇹🇷 Istanbul, Turkey